Hypertension & Pulmonary Hypertension

🔍 Definition

Systemic hypertension (HTN) is a chronic medical condition defined as persistently elevated arterial blood pressure — classically ≥130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline, and ≥140/90 mmHg per older JNC 7 criteria. In ICD-10-CM, there are no BP thresholds or severity descriptors (mild/moderate/severe) embedded in the code structure — the classification hinges on documented hypertension type, presumed or documented causality, organ involvement, and complications. The FY 2027 ICD-10-CM Official Guidelines section I.C.9 governs hypertension coding and its presumed causal relationships.

Pulmonary hypertension (PH) is a hemodynamic and pathophysiological state defined as mean pulmonary arterial pressure (mPAP) >20 mmHg at rest by right heart catheterization, with pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) used to distinguish pre-capillary, post-capillary, and combined forms. Current ESC/ERS guidance defines pre-capillary PH/PAH physiology as mPAP >20 mmHg, PAWP ≤15 mmHg, and PVR >2 Wood units; the older threshold was mPAP ≥25 mmHg. PH encompasses five WHO diagnostic groups with distinct etiologies, treatments, and ICD-10-CM codes. It is distinct from systemic hypertension and is coded in the I27.x category.

Clinical significance for coders and CDI specialists: Hypertension is the most common chronic condition documented in inpatient and outpatient records. Accurate coding — especially capturing hypertensive heart disease (I11.x), hypertensive CKD (I12.x), and the combination (I13.x) — is essential for proper DRG assignment, risk adjustment, quality measures, and HCC capture under CMS HCC Model v28.

⚠️ HCC v28 Note: I10 Does Not Map to an HCC

Under CMS HCC Model v28 (effective 2024, fully phased in 2026), I10 Essential (primary) hypertension alone does not map to any V28 payment HCC. I10 did not map to a payment HCC in V24 either (V24 HCC 85 was heart failure). Risk is captured only when complications — hypertensive heart disease (I11.x), hypertensive CKD (I12.x), heart failure (I50.x), CKD stage (N18.x) — are documented and coded. Ensure all hypertensive complications are captured with specificity.

🗂️ Alternative Terminology

Formal / ICD-10-CM TermColloquial / Lay / Clinical Synonyms
Essential (primary) hypertension (I10)High blood pressure, HTN, HBP, idiopathic hypertension, benign hypertension (outdated), primary HTN
Hypertensive heart disease (I11.x)Hypertensive cardiomyopathy, HTN heart disease, cardiac hypertension, hypertensive LVH with HF
Hypertensive chronic kidney disease (I12.x)Hypertensive nephropathy, HTN-CKD, hypertensive renal disease, hypertension-related CKD
Hypertensive heart and CKD (I13.x)Cardiorenal hypertension, combined hypertensive HF and renal disease, HTN triad
Secondary hypertension (I15.x)Renovascular HTN, endocrine HTN, secondary HBP, hypertension due to renal artery stenosis
Hypertensive urgency (I16.0)Severe asymptomatic hypertension, BP crisis without end-organ damage, stage 3 HTN (informal)
Hypertensive emergency (I16.1)Malignant hypertension (mostly historical), hypertensive crisis with end-organ damage, accelerated HTN
Primary pulmonary arterial hypertension (I27.0)Idiopathic PAH, primary PH, IPAH, sporadic PAH, Group 1 PAH
Secondary pulmonary arterial hypertension (I27.21)Heritable PAH, drug-induced PAH, CTD-associated PAH, Group 1′ PAH
PH due to left heart disease (I27.22)Passive pulmonary hypertension, Group 2 PH, post-capillary PH, pulmonary venous hypertension
PH due to lung diseases/hypoxia (I27.23)Group 3 PH, hypoxic PH, COPD-related PH, ILD-related PH
Chronic thromboembolic PH (I27.24)CTEPH, Group 4 PH, chronic PE with PH, thromboembolic PH
Cor pulmonale, chronic (I27.81)Pulmonary heart disease, right-sided heart failure from lung disease, chronic RV failure
Persistent pulmonary hypertension of newborn (P29.3)PPHN, persistent fetal circulation, neonatal PH
Gestational hypertension (O13.x)Pregnancy-induced HTN, PIH, transient HTN of pregnancy
Preeclampsia (O14.x)Gestational HTN with proteinuria, toxemia (outdated), pre-eclampsia
Eclampsia (O15.x)Toxemia with seizures (outdated), eclamptic convulsions

🩺 Signs & Symptoms

Systemic Hypertension

Systemic hypertension is frequently asymptomatic and discovered incidentally. When symptomatic, common manifestations include:

  • Headache — classically occipital, worse in the morning; may signal hypertensive urgency/emergency
  • Epistaxis — nose bleeds associated with elevated BP
  • Visual changes — blurred vision, scotoma in hypertensive retinopathy (H35.0 with the applicable hypertension code from I10–I15; sequence based on reason for encounter)
  • Dizziness / lightheadedness
  • Palpitations / chest pain — especially with hypertensive heart disease
  • Dyspnea — when hypertensive heart failure (I11.0) has developed
  • Edema — peripheral or pulmonary when concurrent heart failure or CKD is present
  • Hematuria, proteinuria — signs of hypertensive nephropathy (I12.x)
  • End-organ damage signs in HTN emergency (I16.1): papilledema, focal neurological deficits, AKI (elevated creatinine), chest pain (AMI/aortic dissection), pulmonary edema

Pulmonary Hypertension

  • Dyspnea on exertion — earliest and most common symptom; progresses to dyspnea at rest
  • Fatigue and weakness
  • Syncope or pre-syncope — exertional, indicates severe PH
  • Chest pain — right ventricular angina, often exertional
  • Peripheral edema — sign of right heart failure / cor pulmonale (I27.81)
  • Cyanosis — in advanced or shunt-related PH (Eisenmenger syndrome I27.83)
  • Loud P2 (pulmonary component of S2) on auscultation; right ventricular heave
  • Hemoptysis — uncommon; occurs in CTEPH (I27.24) or idiopathic PAH
  • Ascites / hepatomegaly — in advanced cor pulmonale with right ventricular failure
📝 Coder Note — Symptoms vs. Diagnosis

Per ICD-10-CM Official Guidelines I.C.18, when a symptom (e.g., headache, dyspnea) is an integral manifestation of an established diagnosis, code only the diagnosis — not the symptom code. If the symptom is separately documented as a distinct clinical problem requiring additional evaluation, it may be coded additionally.

🧭 Differential Diagnosis

ConditionKey Distinguishing FeaturesPrimary ICD-10-CM Code
Essential (primary) hypertensionNo identifiable secondary cause; most common; diagnosis of exclusion in adultsI10
White coat hypertensionBP elevated only in clinical setting; normal ambulatory BP monitoring (ABPM); use R03.0 if no formal dxR03.0 / I10 if dx confirmed
Secondary — renovascularRenal artery stenosis (atherosclerosis or FMD); abdominal bruit; difficult to controlI15.0
Secondary — renal parenchymalCKD, glomerulonephritis, polycystic kidney disease; elevated creatinineI15.1
Secondary — endocrinePrimary aldosteronism (hypokalemia, adrenal adenoma), Cushing syndrome, pheochromocytoma (paroxysmal HTN, headache, diaphoresis, tachycardia), thyroid diseaseI15.2
Secondary — drug-inducedNSAIDs, oral contraceptives, decongestants, stimulants, cocaine, cyclosporine, erythropoietinI15.8
Hypertensive urgency (I16.0)BP ≥180/120; no end-organ damage; asymptomatic or mild symptomsI16.0
Hypertensive emergency (I16.1)Provider-documented hypertensive emergency; typically severe BP elevation WITH acute end-organ damage (stroke, AMI, AKI, papilledema, aortic dissection)I16.1 + specific EOD code(s); sequence based on reason for encounter
Idiopathic PAH (Group 1)No identifiable cause; diagnosis after exclusion of other PH groups; right heart cath shows pre-capillary PH/PAH physiology (mPAP >20 mmHg, PAWP ≤15 mmHg, PVR >2 Wood units)I27.0
PH due to left heart disease (Group 2)Most common PH; associated with HF with preserved or reduced EF, mitral/aortic valve diseaseI27.22
PH due to lung disease/hypoxia (Group 3)COPD, ILD, obstructive sleep apnea, chronic hypoxemia; often mild PHI27.23
CTEPH (Group 4)History of PE; perfusion scan shows mismatched defects; potentially curable with pulmonary endarterectomyI27.24
Other/multifactorial PH (Group 5)Sarcoidosis, chronic hemolytic anemia, myeloproliferative disorders, metabolic diseasesI27.29
Cor pulmonale (chronic)Right ventricular hypertrophy/failure due to chronic lung disease; distinguish from acute cor pulmonale (I26.0x, which is due to acute PE)I27.81
Gestational hypertensionNew-onset HTN after 20 weeks gestation; no proteinuria; resolves postpartum; code O13.x — NOT I10O13.x
PreeclampsiaHTN + proteinuria ≥300 mg/24h or end-organ damage after 20 weeks; severe features: BP ≥160/110, thrombocytopenia, AKI, impaired liver function, pulmonary edema, new headacheO14.x

📋 Clinical Indicators

Clinical IndicatorDocumentation NeededCode Consideration
BP reading ≥130/80 without HTN diagnosis documentedMD must establish diagnosis; elevated BP alone at one visit ≠ HTN diagnosisR03.0 only (not I10)
HTN documented without complicationsProvider writes “hypertension,” “HTN,” or “high blood pressure” as a diagnosisI10
HTN + heart involvement (I50.-, I51.4–I51.7, I51.89, I51.9)ICD-10-CM presumes the conditions are related under the “with” convention unless the provider documents they are unrelated; query when the documentation is unclear as to the type of heart disease/HF or whether an unrelated cause is documentedI11.0 (with HF) + I50.x type if HF present; I11.9 without HF
HTN + CKD of any stageBoth diagnoses documented; Guidelines I.C.9.a.2 PRESUME causal — no explicit link requiredI12.x + N18.x (automatic presumption — do NOT use I10 + N18.x)
HTN + HF + CKD (triad)All three documented; combination code I13.x usedI13.x + N18.x stage + I50.x HF type
HTN + retinopathyHypertensive retinopathy documentedH35.0 with the applicable hypertension code from I10–I15; sequencing is based on the reason for the encounter
Provider documents hypertensive urgencySevere BP elevation without acute end-organ damage; do not infer hypertensive urgency from BP values aloneI16.0 (HTN urgency) + any identified hypertensive disease code (I10–I15, I1A)
Provider documents hypertensive emergencySevere BP elevation WITH documented acute end-organ damage such as acute MI, ICH, stroke, AKI, papilledema, or aortic dissectionI16.1 + specific EOD code(s); sequence based on reason for encounter
PH documented, type unspecifiedPhysician documents “pulmonary hypertension” without groupingI27.20; query for group/etiology
PAH in context of connective tissue disease (CTD, scleroderma)Both CTD and PAH documented; CTD-associated PAH classified as Group 1′I27.21 + M34.x or other CTD code
Right heart catheterization showing mPAP >20 mmHgResult in notes/procedure report; RHC is the gold standard for PH diagnosis. For pre-capillary PH/PAH, also look for PAWP ≤15 mmHg and PVR >2 Wood units.I27.0–I27.29 depending on group; add associated-condition or drug/adverse-effect codes when applicable
Cor pulmonale documentedDistinguish chronic (I27.81) from acute cor pulmonale (I26.01–I26.09, PE-related); chronic = from chronic lung diseaseI27.81 (chronic) or I26.0x (acute PE)
CTEPH (Group 4 PH)History of PE + chronic thromboembolic obstruction; treated with pulmonary endarterectomy, riociguat, or balloon pulmonary angioplastyI27.24 + I27.82 (chronic PE)
PPHN (newborn)Neonatal diagnosis; high pulmonary vascular resistance; failure of normal circulatory transition at birthP29.3
Pregnancy with pre-existing HTNHTN diagnosed BEFORE pregnancy or ≤20 weeks gestationO10.x (NOT I10 during pregnancy)
💬 CDI Query Trigger — HTN Complication Specificity

When a patient has documented hypertension AND a cardiac finding (left ventricular hypertrophy, diastolic dysfunction, systolic heart failure), the medical record should specify the relationship. If the provider’s documentation does not clearly link the conditions, a compliant CDI query may ask: “Based on the documented findings of [hypertension] and [diastolic dysfunction/systolic heart failure/LVH], is there a causal relationship? If yes, is this hypertensive heart disease with or without heart failure? If heart failure is present, please specify type (systolic/diastolic/combined) and acuity (acute/chronic/acute-on-chronic).” Follow ACDIS/AHIMA query guidelines — queries must be non-leading with multiple choice options including clinical indicators.

🦴 Anatomy & Pathophysiology

Systemic Hypertension

Essential hypertension results from a complex interplay of genetic predisposition and environmental factors that increase systemic vascular resistance (SVR). The renin-angiotensin-aldosterone system (RAAS) plays a central role — angiotensin II causes direct vasoconstriction and stimulates aldosterone release, increasing sodium and water retention. Sympathetic nervous system overactivation, endothelial dysfunction, and impaired nitric oxide bioavailability compound the elevated BP.

End-organ damage pathways:

  • Heart: Pressure overload causes left ventricular hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved EF (HFpEF). Chronic pressure overload may eventually cause systolic dysfunction (HFrEF). The coronary microcirculation also sustains injury, increasing ischemic risk.
  • Kidneys: Hypertension causes glomerular hypertension, progressive nephrosclerosis, and podocyte damage → proteinuria → CKD. Per ICD-10-CM Guidelines I.C.9.a.2, the relationship between HTN and CKD is presumed causal without explicit documentation unless the provider indicates the CKD is not related to the hypertension.
  • Brain: Small vessel disease, lacunar infarcts, cerebral microbleeds, and in HTN emergency, cerebral autoregulation failure → hypertensive encephalopathy (I67.4).
  • Retina: Arteriovenous nicking, copper-wiring, flame hemorrhages, papilledema (grade IV) — coded as H35.0 with the applicable hypertension code from I10–I15; sequencing is based on the reason for the encounter.
  • Aorta: Chronic pressure stress contributes to aortic dissection (I71.x) and aneurysm formation.

Pulmonary Hypertension

In PAH (Group 1), vasoconstriction, smooth muscle proliferation, endothelial dysfunction, and thrombosis in situ narrow the pulmonary arterioles, raising pulmonary vascular resistance (PVR). The right ventricle (RV) initially adapts via hypertrophy, but eventually fails — manifesting as cor pulmonale (I27.81). Key vasoactive imbalances: reduced prostacyclin (vasodilator), reduced nitric oxide, elevated endothelin-1 (potent vasoconstrictor and proliferative agent). Targeted PAH therapies address these pathways (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, soluble guanylate cyclase stimulators).

In Groups 2–5, the mechanism differs by etiology: Group 2 PH occurs from elevated pulmonary venous pressure transmitted backward from left-sided cardiac disease; Group 3 from chronic hypoxic vasoconstriction; Group 4 from mechanical obstruction of pulmonary vessels by organized thrombus; Group 5 from miscellaneous mechanisms including extrinsic compression or metabolic derangements.

💊 Medication Impact / Treatment

Antihypertensive Medication Classes (Systemic HTN)

Chronic antihypertensive pharmacotherapy should be documented in the medical record and may be flagged with long-term drug use code Z79.899 (Other long-term drug use). Key classes:

  • ACE inhibitors / ARBs — first-line for HTN with CKD/proteinuria and hypertensive HF; renal-protective. E.g., lisinopril, enalapril (ACEi); losartan, valsartan (ARB). ARNI (sacubitril/valsartan) for HFrEF.
  • Thiazide / thiazide-like diuretics — hydrochlorothiazide, chlorthalidone; first-line in many guidelines.
  • Calcium channel blockers (CCB) — amlodipine; first-line; especially for older adults and isolated systolic HTN.
  • Beta-blockers — metoprolol succinate, carvedilol; preferred with hypertensive heart disease/HF; atenolol for rate control.
  • Aldosterone antagonists — spironolactone, eplerenone; used in resistant HTN and primary aldosteronism (I15.2).
  • Loop diuretics — furosemide (J1940), bumetanide; for volume overload with HTN + HF or CKD stage 4-5.
  • Alpha-1 blockers, central agonists (clonidine), direct vasodilators (hydralazine) — adjunctive.
  • IV antihypertensives for HTN emergency — nicardipine, labetalol, clevidipine, esmolol, nitroprusside; coded per IV drug administration.
  • Epoetin alfa in ESRD — Q4081 (HCPCS); secondary polycythemia can contribute to elevated BP.

PAH-Specific Therapies

PAH requires specialized treatments targeting the pathobiological pathways. Oral agents are generally covered under Medicare Part D; IV/SC/inhaled agents may be covered under Part B or DME:

  • Endothelin receptor antagonists (ERAs) — bosentan (Tracleer), ambrisentan (Letairis), macitentan (Opsumit); oral — Part D. Require REMS programs due to hepatotoxicity/teratogenicity risk.
  • PDE-5 inhibitors — sildenafil (Revatio), tadalafil (Adcirca); oral — Part D.
  • Soluble guanylate cyclase (sGC) stimulators — riociguat (Adempas); oral — Part D. CONTRAINDICATED with PDE-5 inhibitors.
  • Prostacyclin analogues / pathway agonists:
    • Epoprostenol (Flolan, Veletri) IV continuous — J1325 for epoprostenol drug supply when separately billable; ambulatory infusion pump E0781 may apply for covered external infusion pump use; Part B DME pump rules vary by payer
    • Treprostinil SC/IV (Remodulin) — J3285 for treprostinil injection when separately billable; inhaled treprostinil (Tyvaso) — J7686 when covered under nebulizer/DME policy
    • Iloprost inhaled (Ventavis) — J3490
  • Selexipag (Uptravi) — oral prostacyclin receptor agonist; Part D.

Documentation of specific PAH therapy should prompt CDI review to ensure appropriate PAH group coding (I27.0, I27.21–I27.29) and confirmation that right heart catheterization values are captured in the record.

⚠️ Common Pitfall — Riociguat + PDE-5 Inhibitor Contraindication

Riociguat (Adempas) and PDE-5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated together due to risk of severe hypotension. When auditing medication records in PAH patients, flag concurrent use for physician review. This is a black-box warning from the FDA.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT procedure coding, HCC v28 risk adjustment mapping, CDI query templates, MS-DRG impact, and a complete audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines

Guideline I.C.9.a — Hypertension

The FY2026 ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.9.a, provides the following rules for hypertension:

I.C.9.a.1 — Hypertension with Heart Disease

ICD-10-CM presumes a causal relationship between hypertension and heart involvement and between hypertension and kidney involvement because the conditions are linked by “with” in the Alphabetic Index. Code the conditions as related even without provider documentation explicitly linking them, unless the documentation clearly states they are unrelated. Assign a code from I11.x for hypertension with one or more heart conditions classified to I50.-, I51.4–I51.7, I51.89, or I51.9. Assign I11.0 when heart failure is documented, plus additional code(s) from I50.x to identify the type of heart failure. Assign I11.9 when no heart failure is present.

📝 Coder Note — “With” Convention (Guideline I.A.15)

Per Guideline I.A.15, “The word ‘with’ or ‘in’ should be interpreted to mean ‘associated with’ or ‘due to’ when it appears in a code title, the Alphabetic Index, under a main term, or an instructional note in the Tabular List.” The provider does not need to explicitly document the link when the Alphabetic Index connects two conditions with “with.” However, for hypertension + heart disease, the combination codes exist in the index — coders must follow them when the documentation supports the link.

I.C.9.a.2 — Hypertensive Chronic Kidney Disease

The relationship between hypertension and CKD is presumed causal per ICD-10-CM Guidelines, regardless of whether the provider documents the link, unless the provider indicates the CKD is not related to the hypertension. When a patient has both hypertension and CKD, assign a code from I12.x, with the appropriate N18.x code as an additional code to identify the CKD stage. Do NOT separately code I10 + N18.x when the presumed causal relationship applies. CKD without hypertension uses N18.x alone. Hypertension without CKD uses I10.

I.C.9.a.3 — Hypertensive Heart and Chronic Kidney Disease

When a patient has hypertension, heart disease/heart failure, AND CKD simultaneously, assign the appropriate combination code from I13.x. This is required regardless of whether all three conditions are explicitly linked. Use additional codes for the type of heart failure (I50.x) and CKD stage (N18.x).

I.C.9.a.4 — Secondary Hypertension

Secondary hypertension codes (I15.x) are assigned when an identifiable underlying cause is documented. Two codes are required: one to identify the underlying etiology and one from category I15 to identify the hypertension (e.g., renal artery stenosis I70.1, primary hyperaldosteronism E26.0x, pheochromocytoma D35.0x, Cushing syndrome E24.x). Sequencing is determined by the reason for admission/encounter.

I.C.9.a.10 — Hypertensive Crisis

Assign a code from category I16 for documented hypertensive urgency, hypertensive emergency, or unspecified hypertensive crisis. Code also any identified hypertensive disease (I10–I15, I1A); sequencing is based on the reason for the encounter. If the documentation supports hypertensive emergency and a specific end-organ damage condition (e.g., acute MI I21.x, intracerebral hemorrhage I61.x, AKI N17.x), code the EOD condition as well; I16.1 does not replace the specific EOD code. I.C.9.a.12 — Resistant Hypertension: Assign I1A.0 as an additional code when apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension is documented by the provider. Sequence the code for the specific type of existing hypertension first, if known.

I.C.9.a.11 — Pulmonary Hypertension Pulmonary hypertension is classified to category I27, Other pulmonary heart diseases. For secondary pulmonary hypertension (I27.1, I27.2-), code also any associated conditions or adverse effects of drugs or toxins. Sequencing is based on the reason for the encounter, except for adverse effects of drugs. I.C.9.a.12 — Hypertension, Resistant Resistant hypertension refers to blood pressure that remains above goal despite antihypertensive medications. Assign I1A.0, Resistant hypertension, as an additional code when apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension is documented by the provider. Sequence the code for the specific type of existing hypertension first, if known. Guideline I.C.9.b — Atherosclerotic Coronary Artery Disease and Angina

When CAD coexists with HTN, code both separately unless the documentation explicitly links them as part of the same disease process. CAD uses I25.x; hypertension uses I10/I11.x as appropriate.

Pregnancy Hypertension — Guideline I.C.15

During pregnancy, childbirth, and the puerperium, hypertension conditions use codes from Chapter 15 (O00–O9A), NOT codes from Chapter 9 (I00–I99). Pre-existing hypertension complicating pregnancy uses O10.x (by type: essential, secondary, pre-existing heart disease, CKD). Gestational hypertension without proteinuria uses O13.x. Gestational hypertension with proteinuria (preeclampsia) uses O14.x. Eclampsia uses O15.x.

Pediatric and Neonatal Pulmonary Hypertension — Guideline I.C.16

Persistent pulmonary hypertension of the newborn (PPHN) is coded P29.3. This condition reflects failure of the normal circulatory transition at birth, with high pulmonary vascular resistance and right-to-left shunting. It is distinct from PAH in adults and does not use I27.x codes.

HTN Coding Algorithm

  1. Elevated BP at visit, no HTN diagnosis: → R03.0 only; do not infer HTN diagnosis
  2. HTN documented, no complications: → I10
  3. HTN + documented heart disease/HF: → I11.0 (with HF) + I50.x type; or I11.9 (without HF)
  4. HTN + CKD of any stage: → Presume causal → I12.x + N18.x stage (do not use I10 + N18.x)
  5. HTN + HF + CKD: → I13.x + N18.x + I50.x
  6. Secondary HTN with identifiable cause: → I15.x + underlying cause code
  7. BP ≥180/120: → I16.0 (urgency, no EOD) or I16.1 (emergency, with EOD) + EOD codes
  8. Pregnancy + HTN: → O10.x–O16.x (NOT I10)
🛡️ Audit Alert — Most Common HTN Coding Errors
  • Coding I10 + N18.x separately instead of I12.x — automatic presumption of causal link is missed
  • Omitting I50.x type when I11.0 or I13.0/I13.2 is coded — combination code requires additional HF type
  • Using I10 during pregnancy instead of O10.x–O16.x
  • Coding HTN urgency (I16.0) when documentation supports emergency (I16.1) — EOD evidence in record not coded
  • Coding I27.20 (PH unspecified) when group classification is documented — query for group increases RAF and clinical specificity
  • Omitting N18.x stage code when coding I12.x or I13.x — stage always required as additional code

🔢 ICD-10-CM Code Set (Tabular)

Systemic Hypertension — I10–I16

CodeDescriptionNotes / Coding Tips
I10Essential (primary) hypertensionUse when no documented hypertensive complication. No HCC v28 alone. Not mapped in V24 or V28. Most frequently coded diagnosis in the US.
I11.0Hypertensive heart disease with heart failureMust add I50.x for type of HF. Maps to HCC 226 in V28; the I50.- code may map to HCC 222, 224, or 225.
I11.9Hypertensive heart disease without heart failureNo HCC v28 alone. Use when cardiac manifestation (LVH, etc.) documented but no HF.
I12.0Hypertensive CKD with CKD stage 5 or end-stage renal diseaseAdd N18.5 (stage 5) or N18.6 (ESRD). HCC 326 (N18.5 and N18.6 also map to HCC 326).
I12.9Hypertensive CKD with CKD stages 1–4 or unspecifiedAdd N18.1–N18.4 or N18.9. I12.9 has no HCC; N18.4 → 327, N18.32 → 328, N18.30/N18.31 → 329.
I13.0Hypertensive heart and chronic kidney disease with heart failure and CKD stages 1–4 or unspecified CKDAdd N18.x stage + I50.x HF type. I13.0 maps to HCC 226; the CKD stage code adds its own HCC (327–329).
I13.10Hypertensive heart and chronic kidney disease without heart failure, with CKD stages 1–4 or unspecified CKDNo HF present. Add N18.x. I13.10 has no HCC; the CKD stage code maps by stage (327–329).
I13.11Hypertensive heart and chronic kidney disease without heart failure, with CKD stage 5 or ESRDCKD stage 5/ESRD without HF. Add N18.5 or N18.6. HCC 326.
I13.2Hypertensive heart and chronic kidney disease with heart failure and CKD stage 5 or ESRDAll three: HTN + HF + ESRD. Add N18.5/N18.6 + I50.x HF type. HCC 226 + 326.
I15.0Renovascular hypertensionDue to renal artery stenosis (atherosclerosis I70.1 or FMD Q27.1x). Code underlying cause additionally.
I15.1Hypertension secondary to other renal disordersCKD as cause (distinct from HTN causing CKD, which is I12.x). Glomerulonephritis, polycystic kidney. Add underlying renal dx.
I15.2Hypertension secondary to endocrine disordersCushing (E24.x), primary aldosteronism (E26.x), pheochromocytoma (D35.0x / C74.1x). Add the endocrine dx.
I15.8Other secondary hypertensionDrug-induced (add T-code for drug), sleep apnea-induced, coarctation of aorta.
I15.9Secondary hypertension, unspecifiedUse only when secondary HTN confirmed but cause unidentifiable; query for specificity.
I16.0Hypertensive urgencyBP ≥180/120 mmHg without end-organ damage. New FY2018 code. No HCC.
I16.1Hypertensive emergencyBP ≥180/120 WITH end-organ damage (AMI, ICH, AKI, papilledema, aortic dissection). Code EOD additionally. No standalone HCC.
I16.9Hypertensive crisis, unspecifiedUse only when urgency/emergency is not documented; query for specificity.
I1A.0Resistant hypertensionAdditional code for apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension. Sequence the specific type of existing hypertension first, if known.
I97.3Postprocedural hypertensionUse when postoperative/postprocedural hypertension is documented as a complication of a procedure.
I67.4Hypertensive encephalopathyDistinct from I16.1; represents cerebral manifestation. Use with I10/I11.x as applicable.
H35.0Background retinopathy and retinal vascular changes (incl. hypertensive retinopathy)Use H35.0 along with the applicable hypertension code from I10–I15; sequencing is based on the reason for the encounter.

Pulmonary Hypertension — I27.x

CodeDescriptionWHO Group / Notes
I27.0Primary pulmonary hypertensionGroup 1 — Idiopathic PAH (IPAH); no identifiable cause. HCC 226 v28.
I27.1Kyphoscoliotic heart diseasePulmonary heart disease due to kyphoscoliosis; distinct from other PH groups.
I27.20Pulmonary hypertension, unspecifiedUse when type/group not documented; query for specificity. HCC 226 v28.
I27.21Secondary pulmonary arterial hypertensionGroup 1′ — Heritable PAH, CTD-associated (scleroderma, MCTD, SLE), drug/toxin-induced, HIV-associated, portopulmonary, CHD-associated. HCC 226.
I27.22Pulmonary hypertension due to left heart diseaseGroup 2 — Most common cause of PH; due to HFpEF, HFrEF, mitral/aortic valve disease. Add I50.x or valvular code. HCC 226.
I27.23Pulmonary hypertension due to lung diseases and hypoxiaGroup 3 — COPD (J44.x), ILD (J84.x), OSA (G47.33), chronic hypoxia. Add lung disease code. HCC 226; COPD maps separately (HCC 280).
I27.24Chronic thromboembolic pulmonary hypertensionGroup 4 — CTEPH; prior PE with incomplete resolution; treated with PEA surgery, riociguat, balloon PTA. Add I27.82 (HCC 267). HCC 226.
I27.29Other secondary pulmonary hypertensionGroup 5 — Multifactorial/unclear: sarcoidosis, PVOD, chronic hemolytic anemia, metabolic, compression. HCC 226.
I27.81Cor pulmonale (chronic)RVH/RV failure due to chronic lung disease. HCC 226. Distinct from acute cor pulmonale I26.01-I26.09.
I27.82Chronic pulmonary embolismRequires prior PE; use with I27.24 for CTEPH. HCC 267. See PE CDG.
I27.83Eisenmenger’s syndromeCongenital heart defect with reversed shunt and severe PH; link to Congenital Heart CDG. HCC 226.
I27.89Other specified pulmonary heart diseasesPulmonary vascular disease NOS, pulmonary arteritis. HCC 226.
I27.9Pulmonary heart disease, unspecifiedUse only when no specificity available; query for group. HCC 226.

Pregnancy-Related Hypertension Codes

Code RangeDescriptionNotes
O10.xPre-existing hypertension complicating pregnancy, childbirth, puerperiumHTN diagnosed before pregnancy or <20 weeks gestation. Subclassified by: .0 essential HTN, .1 pre-existing HTN heart disease, .2 pre-existing HTN CKD, .3 both, .4 secondary HTN, .9 unspecified; further specified by trimester/puerperium. See Pregnancy CDG.
O11.xPre-existing HTN with pre-eclampsiaBy trimester/puerperium.
O12.xGestational edema and proteinuria without HTNEdema with or without proteinuria but no HTN dx.
O13.xGestational HTN (induced) without significant proteinuriaNew-onset after 20 weeks; no proteinuria; by trimester/puerperium.
O14.xGestational HTN with proteinuria (preeclampsia)O14.0 mild, O14.1 severe, O14.2 HELLP, O14.9 unspec; by trimester/puerperium.
O15.xEclampsiaIn pregnancy, delivery, puerperium; with/without HF.
O16.xUnspecified maternal hypertensionBy trimester/puerperium; use only when type undocumented.

Neonatal/Pediatric Codes

CodeDescriptionNotes
P29.3Persistent pulmonary hypertension of newborn (PPHN)Failure of normal circulatory transition; high PVR with right-to-left shunting; treated with iNO, ECMO.
P29.4Transient myocardial ischemia in newbornPerinatal myocardial injury; may coexist with PPHN.
P29.8Other cardiovascular disorders originating in perinatal periodIncludes other neonatal cardiac conditions not elsewhere classified.
P22.8Other respiratory distress of newbornMay include secondary PPHN from respiratory causes.

Frequently Associated Comorbidity Codes

CodeDescriptionRelevance to HTN/PH
I50.xHeart failure (by type)Always add when coding I11.0, I13.0, I13.2 — required as additional code
N18.xCKD stage 1–5, ESRD (N18.1–N18.6, N18.9)Always add when coding I12.x or I13.x — required as additional code. See Renal CDG.
R03.0Elevated BP reading without HTN diagnosisUse when BP elevated at visit but no documented HTN diagnosis
G47.33Obstructive sleep apnea (adult)Common comorbidity; OSA contributes to resistant HTN and Group 3 PH
E66.01 / E66.811–E66.813Obesity (morbid, severe)Major HTN risk factor and comorbidity; E66.01 and E66.813 map to HCC 48; E66.811 and E66.812 do not. See Obesity CDG.
E11.xType 2 diabetes mellitusCommon comorbidity with HTN; DM + HTN often = CKD triad. See DM CDG.
F17.2xxNicotine dependenceMajor cardiovascular risk factor; document and code per Guidelines
Z79.899Other long-term drug use (antihypertensives)Document long-term antihypertensive therapy
Z86.79Personal history — other circulatory system diseasesPrior HTN-related events not currently active
R93.1Abnormal findings on diagnostic imaging of heartAbnormal echo/cardiac imaging without specific diagnosis
N25.81Secondary hyperparathyroidism of renal originComplication of CKD in hypertensive CKD patients

🔎 Indexing

Key alphabetic index entries in ICD-10-CM FY 2027 for hypertension and pulmonary hypertension:

Index Lookup TermLeads ToCode
Hypertension, hypertensive (arterial) (benign) (essential)Main entryI10
Hypertension, with heart disease / heart failureCombination entry — I11.xI11.0 (with HF), I11.9 (without HF)
Hypertension, with chronic kidney diseaseCombination entry — I12.x, by stageI12.0 (stage 5/ESRD), I12.9 (stages 1-4)
Hypertension, with heart disease and chronic kidney diseaseI13.x by HF + CKD stageI13.0, I13.10, I13.11, I13.2
Hypertension, secondaryI15.x by causeI15.0–I15.9
Hypertension, renovascularDirect entryI15.0
Hypertension, due to endocrine disorderI15.2I15.2
Hypertensive crisisI16.xI16.0 urgency, I16.1 emergency, I16.9 unspec
Hypertension, resistantI1A.0Additional code for apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension
Hypertension, pulmonary (arterial) (idiopathic) (primary)I27.0I27.0
Hypertension, pulmonary, secondaryI27.21–I27.29 by typeI27.21–I27.29
Hypertension, pulmonary, due to left heart diseaseI27.22I27.22
Hypertension, pulmonary, thromboembolic (chronic)I27.24I27.24
Cor pulmonale (chronic)I27.81I27.81
Cor pulmonale (acute)I26.09I26.09 (with acute PE)
Hypertension, gestationalO13.xO13.x by trimester
Pre-eclampsiaO14.xO14.0/O14.1/O14.2/O14.9
EclampsiaO15.xO15.0–O15.9
Blood pressure, elevatedR03.0R03.0
Retinopathy, hypertensiveH35.0 (code first HTN)I10 first, then H35.0
Encephalopathy, hypertensiveI67.4I67.4

🏥 CPT

The following CY2027 CPT codes are commonly associated with hypertension diagnosis, monitoring, and management, as well as pulmonary hypertension workup and treatment.

CPT CodeDescriptionTypical UseNotes
93784Ambulatory BP monitoring (ABPM), 24-hour with physician review/analysisConfirms white-coat vs. true HTN; masked HTNAlso 93786 (recording only), 93788 (scanning analysis), 93790 (physician review only). For Medicare ABPM billing, verify current payer-specific rules and coverage limits.
93786ABPM, recording onlyTechnical component of ABPMPaired with 93790 or 93788
93788ABPM, scanning analysis with reportTechnical + summary
93790ABPM, review with physician report/interpretationPhysician component
93000Electrocardiogram, routine 12-lead with interpretationLVH evaluation, arrhythmia screen in HTN93005 tracing only; 93010 interpretation only
93040Rhythm EKG, 1–3 leadsRate/rhythm check in HTN management93041 tracing, 93042 interpretation
93306Echocardiography, transthoracic, complete (M-mode, 2D, Doppler)LVH assessment, EF, valvular evaluation in HTN; PAH diagnosisMost important test for HTN cardiac evaluation. 93307 limited, 93308 follow-up.
93350Stress echocardiography (exercise or pharmacologic), completeIschemic evaluation, HFpEF stress testing93351 with supervision
93224Continuous EKG monitoring (Holter), 48 hours, with analysis and interpretationArrhythmia evaluation in hypertensive patients93225 recording, 93226 scanning, 93227 review/interpretation. 93224–93227 series.
93228External EKG rhythm derivation with continuous monitoring, 2–14 daysExtended rhythm monitoring in HTN patients93229 physician interpretation; 93268–93272 event monitor codes.
93270Wearable mobile cardiac telemetry, heart rhythm, includes analysis 30 daysRemote cardiac monitoring93271 recording, 93272 analysis/interpretation
93452Left heart catheterization (LHC)Coronary and LV pressure measurement; HTN-related CAD workup93458/93459/93460/93461/93462 include coronary/LV angiography combinations
93530Right heart catheterization (RHC), for congenital cardiac anomaliesRHC in complex congenital PH (Eisenmenger)93531–93533 RHC with LHC combinations. Gold standard for PAH: measure mPAP, PCWP, PVR.
93451Right heart catheterization (adult/acquired heart disease)Gold standard PAH diagnosis: mPAP ≥20 mmHg at rest, PCWP ≤15 mmHg (Group 1)Vasodilator challenge (adenosine/iNO) performed during RHC for PAH reversibility testing
93563Injection procedure for selective pulmonary arteriogramPAH evaluation: pulmonary angiography for CTEPH diagnosisPerformed during RHC or separate catheterization
71260CT thorax with contrastPAH workup: mediastinal adenopathy, pulmonary fibrosis, CTEPH (filling defects)71275 CT angiography thorax
76770Retroperitoneum ultrasound, completeRenal artery evaluation for renovascular HTN76775 limited retroperitoneum US; renal duplex Doppler 93975/93976
80053Comprehensive metabolic panelBaseline and monitoring: creatinine, BUN, Na, K, glucose, LFTs for HTN managementIncludes 82565 creatinine, 84132 potassium, 84295 sodium, 84520 BUN, 82040 albumin
84484Troponin, quantitativeEnd-organ damage (AMI) in HTN emergency (I16.1)Add 83605 lactate for EOD severity assessment
83605LactateShock/end-organ failure assessment in HTN emergency
99490Chronic care management (CCM), 20 minutes/month, complex chronic conditionsOngoing HTN management in outpatient setting99439 additional 20 min; 99491/99437 provider-performed CCM
99424 / +99425Principal care management (PCM), physician/QHP personally provided; first 30 min / each additional 30 min per calendar monthSingle high-risk condition management for complex HTN with significant risk and frequent medication or care-plan adjustmentsUse 99425 only with 99424. Clinical staff PCM uses 99426 first 30 min and +99427 each additional 30 min, directed by physician/QHP.
93793Anticoagulant management (INR), outpatientHTN patients on warfarin for afib, VTE, or valve disease
93797Cardiac rehabilitation, per session (without monitoring)Post-HTN complications (post-MI, post-HF)93798 with monitoring
📝 Coder Note — RHC for PAH Diagnosis

Right heart catheterization (93451) is the gold standard for PAH diagnosis per international PAH guidelines. Diagnosis requires mPAP >20 mmHg at rest with pulmonary capillary wedge pressure (PCWP/PAWP) ≤15 mmHg and PVR >2 Wood units (for Group 1 PAH). When RHC results appear in the record showing mPAP >20 mmHg, ensure a specific I27.x code (not just I27.20) is captured in the problem list and discharge summary.

🧾 HCPCS

HCPCS CodeDescriptionTypical Use in HTN/PH
J1940Furosemide injection, 20 mgIV loop diuretic for volume overload in HTN with HF or CKD; acute decompensated HF
J1325 / J3285 / J7686 / Q4074PAH prostacyclin-pathway drug supply codesEpoprostenol injection (J1325), treprostinil injection (J3285), treprostinil inhalation solution (J7686), and iloprost inhalation solution (Q4074) have specific HCPCS codes when payer coverage and billing circumstances support separate reporting. Use J3490 only when no specific HCPCS code applies and payer policy supports an unclassified drug code.
J7999Compounded drug, not otherwise classifiedCompounded preparations for PAH infusion management
J1642Heparin sodium, per 10 unitsAnticoagulation in CTEPH; central line maintenance in PAH infusion patients
J1650Enoxaparin sodium, 10 mgAnticoagulation in HTN patients with afib, VTE, or CTEPH (I27.24)
Q4081Epoetin alfa injection, 100 units (ESRD use)Anemia of CKD in hypertensive CKD/ESRD patients; Part B ESRD facility or non-ESRD physician office
E0781Ambulatory infusion pump, single or multiple channels, per dayContinuous IV/SC prostacyclin infusion (epoprostenol, treprostinil) — DME Part B; essential for PAH treatment
E1390Oxygen concentrator, single delivery port, 85% or greater concentration at restStationary home O2 for chronic hypoxic PH (Group 3) or severe PAH; requires SpO2 documentation
E0434Portable liquid oxygen system, rental, including portable container, supply of liquid oxygen, tubing, flow regulator, etc.Portable O2 for ambulatory PH patients
E0435Portable liquid oxygen contents, per unitRefill for portable liquid O2
E0601Continuous airway pressure (CPAP) deviceOSA comorbidity with HTN/PH (G47.33); treatment of OSA reduces BP and PH Group 3 contribution
J0270Alprostadil injection, 1.25 mcgNeonatal ductal patency for ductal-dependent congenital heart disease/PH physiology; not adult PAH therapy and not routine PPHN management. Verify payer and NDC-specific billing.
J0500–J0550Dicyclomine / Atropine (older coding)Not HTN-specific; included for awareness — do not confuse with antihypertensive J-codes
J3380Not PAH relatedVedolizumab — GI biologic; listed for avoidance; not a PAH code
Note: Oral PAH agentsSildenafil (Revatio), tadalafil (Adcirca), bosentan (Tracleer), ambrisentan, macitentan, riociguat, selexipagOral agents covered under Medicare Part D (not Part B); no HCPCS J-code for Part B. Verify formulary tier for prior authorization.

📚 AHA Coding Clinic

The following guidance from the AHA Coding Clinic for ICD-10-CM/PCS is relevant to hypertension and pulmonary hypertension coding:

TopicGuidance SummarySource
HTN + CKD Presumed CausalitySection I.C.9.a.2 presumes a causal relationship between hypertension and CKD: assign a code from category I12 when both are present, with a code from category N18 to identify the stage of CKD. CKD should not be coded as hypertensive if the provider indicates the CKD is not related to the hypertension. Coding Clinic, 4Q 2018: when the provider documents type 2 diabetes with CKD and the patient also has hypertension, assign E11.22, I12.9, and N18.9, because the classification presumes both relationships. Coding Clinic, 3Q 2019: when the provider documents CKD due to diabetes, diabetic CKD, diabetic nephropathy, or similar terminology, a causal relationship is indicated and denotes the CKD is not related to the hypertension; assign the diabetic CKD code, code the hypertension separately rather than as hypertensive CKD, and do not assign both E11.21 and E11.22.Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.2; AHA Coding Clinic, 4Q 2018, “Hypertension, Diabetes Mellitus and Chronic Kidney Disease“; AHA Coding Clinic, 3Q 2019, “Hypertension with Diabetic Nephropathy and Chronic Kidney Disease“
I10 Removed from HCC v28CMS removed I10 from HCC mapping in v28 risk adjustment model. I10 alone no longer generates RAF credit. Downstream complications must be coded with specificity (I11.x, I12.x, I13.x + N18.x + I50.x).CMS v28 Announcement 2023; CMS Risk Adjustment
Hypertensive Urgency and Emergency CodesI16.0 (hypertensive urgency), I16.1 (hypertensive emergency), and I16.9 (hypertensive crisis, unspecified) were created effective October 1, 2016 (FY 2017), as described in Coding Clinic, 4Q 2016. Section I.C.9.a.10 directs a code from category I16 for documented hypertensive urgency, emergency, or crisis, and to code also the hypertensive disease (I10-I15, I1A); sequencing is based on the reason for the encounter. In the Coding Clinic example, the end-organ condition (I61.0) is sequenced first, followed by I16.1 and I10. Accelerated or malignant hypertension without documentation of crisis is assigned I10.AHA Coding Clinic, 4Q 2016, “Hypertensive Crisis, Urgency and Emergency“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.10
PAH Group Coding Post-2020 ICD-10 ExpansionThe I27.2- expansion, effective October 1, 2017 (FY 2018) and described in Coding Clinic, 4Q 2017, classifies pulmonary hypertension by group: I27.21 (secondary pulmonary arterial hypertension, group 1), I27.22 (group 2, due to left heart disease), I27.23 (group 3, due to lung disease and/or hypoxia), I27.24 (group 4, chronic thromboembolic), and I27.29 (group 5, other secondary). I27.0 remains primary pulmonary hypertension. Assign I27.20, Pulmonary hypertension, unspecified, when the type is not documented. Follow the code also notes for associated conditions and adverse effects (Section I.C.9.a.11).AHA Coding Clinic, 4Q 2017, “Pulmonary Hypertension“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.11
Cor Pulmonale: Acute vs. ChronicI27.81, Cor pulmonale (chronic), includes cor pulmonale NOS, has a code also note for right heart failure (I50.81-), and has an Excludes1 note for acute cor pulmonale (I26.0-). Acute cor pulmonale NOS is an inclusion term at I26.09, Other pulmonary embolism with acute cor pulmonale. Coding Clinic, 4Q 2014, advised that I26.09 is not appropriate for acute cor pulmonale due to pulmonary hypertension without pulmonary embolism; that advice predates the I27.2- and I50.81- expansions.Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Tabular List of Diseases and Injuries FY 2027, codes I27.81 and I26.09; AHA Coding Clinic, 4Q 2014, “Acute Cor Pulmonale due to Pulmonary Hypertension without Mention of Pulmonary Embolus“
Hypertensive Retinopathy SequencingWhen hypertensive retinopathy is documented, assign H35.0 along with the applicable hypertension code from I10–I15. Sequencing is based on the reason for the encounter.ICD-10-CM Official Guidelines I.C.9.a.5; ICD-10-CM Tabular List
Pregnancy and Pre-existing HTNChronic hypertension in pregnancy is pre-existing hypertension and is coded to category O10 (Coding Clinic, 2Q 2025); assign O10.91- when the type of pre-existing hypertension is not specified. O10.0- includes any condition in I10 specified as a reason for obstetric care, so I10 is not added. For pre-existing hypertensive heart disease (O10.1-) or hypertensive CKD (O10.2-), add a secondary code from the appropriate hypertension category (I11 or I12) to specify the type of heart failure or CKD (Section I.C.15.d). Select the O10 code for the episode: pregnancy by trimester, childbirth, or the puerperium.AHA Coding Clinic, 2Q 2025, “Chronic Hypertension in Pregnancy“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.15.d
CTEPH Coding (I27.24 + I27.82)Chronic thromboembolic pulmonary hypertension (group 4) is assigned I27.24 (Coding Clinic, 4Q 2017). I27.24 has a code also note for associated pulmonary embolism, if applicable (I26.-, I27.82), so report I27.82, Chronic pulmonary embolism, when the provider documents it. I27.82 has a use additional code note for long term (current) use of anticoagulants, if applicable (Z79.01), and an Excludes1 note for personal history of pulmonary embolism (Z86.711).AHA Coding Clinic, 4Q 2017, “Pulmonary Hypertension“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Tabular List of Diseases and Injuries FY 2027, codes I27.24 and I27.82
Hypertension Associated with Diabetes, with CKD (I15.2, not I12)When the provider documents hypertension associated with or due to diabetes and the patient has CKD not linked to another condition, assign E11.65 (if hyperglycemia), E11.59, E11.22, I15.2, and the N18 stage code. Do not assign I12: category I12 has an Excludes1 note for I15, and when an Excludes1 note applies only the code it references is assigned (Coding Clinic, 4Q 2018, page 87).AHA Coding Clinic, 2Q 2026, “Chronic Kidney Disease in a Patient with Hypertension Associated with Diabetes”

💰 HCC / Risk Adjustment

Hypertension itself does not map to a V28 payment HCC; its combination codes and the required additional codes carry the risk. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.

ICD-10-CM Code(s)DescriptionV28 HCCCoding / Documentation Notes
I10Essential hypertensionNo V28 payment HCCI10 has not mapped to a CMS-HCC payment HCC in V24 or V28 (V24 HCC 85 was heart failure)
I11.0Hypertensive heart disease with HFHCC 226Also code the HF type (I50.-); the HF code may move the HCC to 222, 224, or 225
I11.9Hypertensive heart disease without HFNo V28 payment HCC—
I12.0Hypertensive CKD with stage 5 CKD or ESRDHCC 326 — CKD, Stage 5Also code N18.5 or N18.6 (also HCC 326)
I12.9Hypertensive CKD with stage 1–4 or unspecified CKDNo V28 payment HCCThe N18 stage code carries the HCC: N18.4 → 327; N18.32 → 328; N18.30, N18.31 → 329; N18.1, N18.2, N18.9 → none
I13.0Hypertensive heart and CKD with HF and stage 1–4 CKDHCC 226Also code the HF type and the CKD stage
I13.10Hypertensive heart and CKD without HF, stage 1–4 CKDNo V28 payment HCCCode the CKD stage
I13.11Hypertensive heart and CKD without HF, stage 5 CKD/ESRDHCC 326Also code N18.5 or N18.6
I13.2Hypertensive heart and CKD with HF and stage 5 CKD/ESRDHCC 226 and HCC 326Also code the HF type and N18.5 or N18.6
I15.-, I16.-, I1A.0Secondary hypertension; hypertensive crisis; resistant hypertensionNo V28 payment HCCThe underlying cause or end-organ damage may map separately
I27.0, I27.20–I27.29, I27.9Primary and secondary pulmonary hypertension (all groups)HCC 226For secondary PH, code also the associated condition (Guideline I.C.9.a.11); COPD maps separately (HCC 280)
I27.81, I27.83, I27.89Chronic cor pulmonale; Eisenmenger syndrome; other pulmonary heart diseaseHCC 226Shares HCC 226 with chronic HF
I27.82Chronic pulmonary embolismHCC 267Add when the provider documents chronic PE; CTEPH (I27.24) is HCC 226

Hypertensive emergency end-organ damage: acute MI (I21.-) → HCC 228; ischemic stroke (I63.-) → HCC 249; intracranial hemorrhage (I60–I62) → HCC 248; aortic dissection (I71.0-) → HCC 264.

💬 Coding Check — Hypertension, HF, and CKD Coded Separately

When the record shows hypertension, heart failure, and CKD coded as I10 + I50.- + N18.-, this is a coding error to correct, not a query. FY 2027 Guideline I.C.9.a presumes the causal relationship; assign I13.- with the HF type and CKD stage. Query only when the provider has stated the conditions are unrelated or the documentation conflicts, and use a compliant, non-leading query.

Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, constraints, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines Section I.C.9. Verified November 3, 2026.

✍️ CDI Query Templates

All queries below are formatted per ACDIS/AHIMA compliant query standards: non-leading, multiple choice, include clinical indicators, identify impact on coding. CDI specialists should use these templates as frameworks, customizing with patient-specific clinical indicators.

Clinical ScenarioQuery Wording (Framework)Code Impact
HTN documented; heart involvement/HF documented but type, acuity, or unrelated cause is unclear“The record documents hypertension and [heart failure / LVH / cardiomegaly / other heart condition]. ICD-10-CM presumes specified heart involvement is related to hypertension unless the provider documents the conditions are unrelated. Please clarify the heart condition and, if heart failure is present, specify type (systolic, diastolic, combined, right heart, other) and acuity (acute, chronic, acute-on-chronic), or document if the heart condition is unrelated to hypertension.”I11.0 + I50.x when HF present; I11.9 without HF; code separately only if documented as unrelated
HTN + CKD documented; coded separately as I10 + N18.x“The patient has documented hypertension and CKD stage [X]. Per ICD-10-CM guidelines, these conditions are presumed causally related. Please confirm whether the CKD is related to or associated with the patient’s hypertension, or if the CKD is independently caused by another condition (e.g., diabetic nephropathy, glomerulonephritis): (A) Hypertensive CKD (hypertension is a contributing factor); (B) CKD due to another specified cause — please specify; (C) Cannot be determined.”I12.x + N18.x (correct) vs. I10 + N18.x (error); the N18 stage code carries the CKD HCC (326–329)
HTN + HF + CKD documented; coded as I11.0 + N18.x (missing I13.x combination)“This patient has documented hypertension, [HF type], and CKD stage [X]. Is there a single disease process linking all three conditions? If so, please document: (A) Hypertensive heart and CKD with heart failure [add CKD stage]; (B) Conditions are separate/unrelated; (C) Cannot determine.”I13.0 → HCC 226 plus the CKD stage HCC; I13.2 → HCC 226 + HCC 326
BP ≥180/120 documented; unclear if end-organ damage present“The patient presented with blood pressure of [X/X] mmHg. Please clarify the clinical assessment: (A) Hypertensive urgency — severely elevated BP without end-organ damage; (B) Hypertensive emergency — severely elevated BP WITH end-organ damage — specify: [check all that apply] AKI, AMI, stroke/TIA, hypertensive encephalopathy, aortic dissection, papilledema; (C) Neither — specify alternative diagnosis; (D) Cannot determine.”I16.0 (urgency, no HCC) vs. I16.1 (emergency) + EOD codes (HCC varies)
Pulmonary hypertension documented; group/etiology not specified“The patient has documented pulmonary hypertension with [RHC showing mPAP X mmHg / echocardiographic findings]. Based on the clinical workup, please classify the pulmonary hypertension: (A) Primary/idiopathic PAH (Group 1 — no identifiable cause); (B) Secondary PAH associated with [CTD/drug/HIV/portal HTN] (Group 1′); (C) PH due to left heart disease — specify type [HFrEF/HFpEF/valvular] (Group 2); (D) PH due to lung disease/hypoxia — specify [COPD/ILD/OSA] (Group 3); (E) Chronic thromboembolic PH — CTEPH (Group 4); (F) Multifactorial/other (Group 5); (G) Cannot determine.”I27.0–I27.29 specific → HCC 226; I27.81 if cor pulmonale → HCC 226
Cor pulmonale documented; acute vs. chronic distinction unclear“Cor pulmonale is documented in this patient. Please clarify: (A) Chronic cor pulmonale — right ventricular hypertrophy/failure due to chronic lung disease (specify: COPD, ILD, other); (B) Acute cor pulmonale — acute right heart strain/failure in the context of acute pulmonary embolism; (C) Cannot determine.”I27.81 (chronic, HCC 226) vs. I26.0x (acute PE with acute cor pulmonale, HCC 267)
Secondary HTN suspected (resistant HTN, endocrine findings, renal artery stenosis on imaging)“This patient has hypertension noted to be difficult to control / with findings suggesting [aldosteronism / pheochromocytoma / renal artery stenosis / Cushing syndrome]. Is the hypertension: (A) Essential/primary hypertension; (B) Secondary hypertension due to renovascular cause (renal artery stenosis); (C) Secondary hypertension due to endocrine cause — specify: primary aldosteronism, pheochromocytoma, Cushing syndrome, other; (D) Secondary hypertension due to another cause — specify; (E) Cannot determine.”I15.x + underlying cause → endocrine HCC if applicable; I10 if primary
Hypertension in pregnant patient coded as I10“This patient is pregnant (currently [X] weeks gestation). The hypertension documented should be classified for the obstetric record: (A) Pre-existing hypertension (diagnosed before pregnancy or <20 weeks) — specify type: essential, secondary, with heart disease, with CKD; (B) Gestational hypertension (new onset ≥20 weeks, without proteinuria); (C) Pre-eclampsia (new onset ≥20 weeks WITH proteinuria or end-organ manifestations) — specify: mild, severe, HELLP; (D) Eclampsia; (E) Cannot determine.”O10.x–O16.x (not I10) — required for compliance per Guidelines I.C.15

🧑‍⚕️ Treatments (Clinical)

Systemic Hypertension — Treatment Overview

Hypertension treatment follows a stepwise approach per the AHA/ACC 2017 Hypertension Guidelines:

  1. Lifestyle modification (first-line for all stages): DASH diet, sodium restriction (<2.3 g/day), weight loss, increased physical activity, moderation of alcohol, smoking cessation. Addresses F17.2xx, E66.x, and E11.x comorbidities.
  2. Stage 1 HTN (130–139/80–89 mmHg with high CVD risk, or Stage 2 ≥140/90): Pharmacotherapy initiated. First-line agents: thiazide diuretics, CCBs, ACE inhibitors, ARBs — choice guided by compelling indications (CKD → ACEi/ARB; HF → beta-blocker, ACEi/ARB, aldosterone antagonist; diabetes → ACEi/ARB).
  3. Resistant hypertension (BP uncontrolled on ≥3 agents including diuretic): Evaluate for secondary HTN (I15.x). Add mineralocorticoid receptor antagonist (spironolactone). Renal denervation is no longer purely investigational in the U.S.; FDA-approved renal denervation systems may be considered as adjunctive treatment for selected patients whose BP remains inadequately controlled despite lifestyle modification and antihypertensive medications, subject to coverage and patient-selection criteria.
  4. Hypertensive urgency (I16.0): Outpatient oral agent dose adjustment; BP goal is gradual reduction over 24–48 hours; avoid rapid reduction (risk of ischemic events). Oral labetalol, amlodipine, or clonidine commonly used.
  5. Hypertensive emergency (I16.1): ICU admission; IV antihypertensives (nicardipine, labetalol, clevidipine, nitroprusside, esmolol depending on end-organ damage type); goal: reduce MAP by ≤25% in first hour, then gradual normalization. Aortic dissection → esmolol + nitroprusside; ischemic stroke → permissive HTN until tPA threshold met; AKI/encephalopathy → nicardipine or labetalol.

Pulmonary Arterial Hypertension — Clinical Treatment

PAH treatment is risk-stratified per current ESC/ERS guidance using low/intermediate/high risk classification based on WHO functional class, 6-minute walk distance, BNP/NT-proBNP, cardiac imaging, and RHC hemodynamics:

  • Low-risk (WHO FC I-II, stable): Oral combination therapy — ERA + PDE-5 inhibitor (e.g., ambrisentan + tadalafil, per AMBITION trial).
  • Intermediate-risk (WHO FC II-III): Oral triple therapy (ERA + PDE-5i + oral prostacyclin receptor agonist [selexipag]); consider transition to parenteral prostacyclin.
  • High-risk (WHO FC III-IV, rapidly deteriorating): IV prostacyclin (epoprostenol, treprostinil) is preferred; IV epoprostenol has the strongest mortality evidence. Bridge to lung transplantation evaluation.
  • Vasodilator-reactive PAH (Group 1): Calcium channel blockers (diltiazem, nifedipine, amlodipine) — ONLY for patients who test positive on acute vasodilator challenge during RHC (minority of IPAH patients).
  • CTEPH (Group 4): Pulmonary endarterectomy (PEA) surgery is the treatment of choice for operable disease; riociguat (Adempas) is approved for inoperable CTEPH; balloon pulmonary angioplasty (BPA) is an emerging option. Lifelong anticoagulation required.
  • Group 2 PH (left heart disease): Treat the underlying cardiac condition (HF, valvular disease). PAH-targeted therapies are generally NOT used and may be harmful in Group 2 PH.
  • Group 3 PH (lung disease/hypoxia): Optimize lung disease treatment; supplemental oxygen; inhaled treprostinil (Tyvaso inhalation solution and Tyvaso DPI) is FDA-approved for PH-ILD to improve exercise ability; Tyvaso DPI was approved in 2022.
  • Lung transplantation: For refractory PAH (Group 1) or CTEPH not amenable to PEA; bilateral lung or heart-lung transplant depending on cardiac involvement. Document evaluation and listing status in record (Z76.82 if awaiting organ transplant; Z94.2 if post-lung transplant).

🎓 Patient Education / Summary

The following summary is designed for patient-facing use or for coding/CDI staff to communicate clinical context to documentation improvement initiatives.

What is Hypertension?

High blood pressure (hypertension) occurs when the force of blood pushing against artery walls is consistently too high. According to the American Heart Association, blood pressure is measured in two numbers: systolic (when the heart beats) over diastolic (when the heart rests). Normal is below 120/80 mmHg. Blood pressure at or above 130/80 mmHg in adults is classified as hypertension.

Why it matters for health: If left uncontrolled, high blood pressure damages blood vessels, the heart, kidneys, brain, and eyes over time. It is often called the “silent killer” because most people with hypertension have no symptoms. Regular monitoring and treatment are essential.

What is Pulmonary Hypertension?

Pulmonary hypertension (PH) is high blood pressure specifically in the lungs’ arteries. It is different from regular (systemic) hypertension. PH forces the right side of the heart to work harder to pump blood through the lungs, eventually leading to right heart failure (cor pulmonale) if untreated. Symptoms include worsening shortness of breath, fatigue, dizziness, and leg swelling. The Pulmonary Hypertension Association (PHA) is a patient resource for diagnosis, treatment, and support.

Key Lifestyle Recommendations (per AHA/ACC Guidelines)

  • DASH diet — rich in fruits, vegetables, whole grains, low-fat dairy; limits sodium, saturated fat, red meat
  • Limit sodium — target <2,300 mg/day (ideally <1,500 mg for HTN patients per DASH-Sodium trial)
  • Regular exercise — 150 min/week moderate-intensity aerobic activity lowers BP by 5–8 mmHg
  • Weight management — each kg of weight loss reduces BP ~1 mmHg
  • Limit alcohol — ≤1 drink/day women, ≤2 drinks/day men
  • Quit smoking — tobacco cessation reduces cardiovascular and renal risk (F17.2xx)
  • Medication adherence — do not discontinue antihypertensives without physician guidance; rebound HTN can occur
  • Home BP monitoring — log readings; typical target <130/80 mmHg at home for most adults per AHA 2017

CDI/Coder Quick Reference Summary

  • I10 alone has NO HCC v28 — capture complications (I11.x, I12.x, I13.x) with full specificity
  • HTN + CKD always → I12.x + N18.x (never I10 + N18.x)
  • HTN + HF → I11.0 + I50.x type (physician link required)
  • HTN + HF + CKD → I13.x + N18.x + I50.x
  • PH Group coding → I27.0–I27.29 (not just I27.20) — query for group
  • Cor pulmonale (I27.81) = HCC 226, the same HCC as pulmonary hypertension and chronic HF
  • PAH prostacyclin-pathway therapies (epoprostenol, treprostinil, iloprost) → use specific HCPCS when applicable (e.g., J1325, J3285, J7686, Q4074) and DME pump/nebulizer codes when covered; verify payer-specific billing rules
  • Pregnancy HTN → always O10.x–O16.x, never I10 during pregnancy
  • PPHN in newborns → P29.3 (not I27.x)


About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY 2027 ICD-10-CM (effective October 1, 2026) and CPT 2027 (effective January 1, 2027). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)

Ready to turn this knowledge into a credential?

These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.

CCO Hero

Know someone starting a medical coding career?

Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.

Become a CCO Hero
Photo of author

CCO Certified Professionals

The CCO Certified Professionals team brings together experienced, credentialed medical coders, CDI specialists, and clinical documentation experts with decades of combined expertise in inpatient, outpatient, and risk-adjustment coding. Every Clinical Documentation Guide is built and reviewed by certified instructors who teach, code, and audit in the field every day. Content is verified against current ICD-10-CM, AHA Coding Clinic, and CMS guidance.

Leave a Comment

Clinical Doc Guides

⚊